BOOK
FDG PET/CT Imaging: Normal Variations and Benign Findings – Translation to PET/MRI, An Issue of PET Clinics, E-Book
(2014)
Additional Information
Book Details
Abstract
This issue of PET Clinics examines normal variations and benign findings in FDG PET/CT Imaging. Topics include Standardization and quantification in FDG PET /CT imaging for staging and restaging of disease, dynamic changes in FDG update in normal tissues, as well as normal variations in the brain, head and neck, thorax, abdomen, pelvis, and in pediatrics.
Table of Contents
| Section Title | Page | Action | Price |
|---|---|---|---|
| Front Cover | Cover | ||
| FDG PET/CT Imaging:Normal Variations and Benign Findings | i | ||
| copyright\r | ii | ||
| Contributors | iii | ||
| Contents | vii | ||
| Pet Clinics\r | x | ||
| Preface\r | xiii | ||
| Standardization and Quantification in FDG-PET/CT Imaging for Staging and Restaging of Malignant Disease | 117 | ||
| Key points | 117 | ||
| Introduction | 117 | ||
| Quantification with SUV measurements in FDG-PET/CT studies | 118 | ||
| Assessment of treatment response in oncology with FDG-PET/CT using SUV measurements | 118 | ||
| Quantification in FDG-PET: the requisites | 120 | ||
| Standardization | 120 | ||
| QC Procedures | 120 | ||
| Qualification of Personnel | 121 | ||
| Errors in quantification in FDG-PET/CT: what can we do? | 122 | ||
| Technical Errors: What Can We Do? | 122 | ||
| Physical Errors: What Can We Do? | 123 | ||
| Biological Errors: What Can We Do? | 124 | ||
| FDG-PET/CT in multicentric clinical trials | 124 | ||
| Summary and next steps | 124 | ||
| Acknowledgments | 125 | ||
| References | 125 | ||
| Brain Normal Variations and Benign Findings\rin Fluorodeoxyglucose-PET/Computed\rTomography Imaging\r | 129 | ||
| Key points | 129 | ||
| Introduction | 129 | ||
| Imaging technique | 130 | ||
| Normal anatomy | 130 | ||
| Imaging findings | 131 | ||
| Scanning Time | 131 | ||
| Age | 132 | ||
| Gender | 134 | ||
| Substances/Medications | 134 | ||
| Therapy Procedures | 136 | ||
| Artifacts | 136 | ||
| Summary | 137 | ||
| References | 137 | ||
| Head and Neck Normal Variations and Benign Findings in\rFDG Positron Emission Tomography/\rComputed Tomography Imaging\r | 141 | ||
| Key points | 141 | ||
| Introduction | 141 | ||
| PET/CT scanning protocols | 141 | ||
| FDG | 142 | ||
| Radiation Doses | 142 | ||
| Scanning Protocol | 142 | ||
| Patient Positioning | 142 | ||
| Acquisition Protocol | 142 | ||
| Image Reconstruction | 142 | ||
| PET/CT image interpretation | 142 | ||
| Physiologic FDG uptake | 142 | ||
| Benign findings | 144 | ||
| Artifacts | 145 | ||
| Summary | 145 | ||
| References | 145 | ||
| Thorax Normal and Benign Pathologic Patterns\rin FDG-PET/CT Imaging | 147 | ||
| Key points | 147 | ||
| Introduction | 147 | ||
| Patterns of FDG biodistribution in the normal thorax | 148 | ||
| Patterns of FDG uptake in benign pathologic processes of the thorax | 155 | ||
| Infection | 155 | ||
| Interstitial Lung Disease, Connective Tissue Disease, and Vasculitides | 157 | ||
| Pneumoconiosis | 158 | ||
| Acute Respiratory Distress Syndrome | 158 | ||
| Treatment-Related Sources of Abnormal FDG Uptake | 158 | ||
| Sarcoidosis | 161 | ||
| Cystic Fibrosis | 162 | ||
| Pulmonary Nodules | 162 | ||
| Chest Trauma | 162 | ||
| Myocardium and Great Vessels | 163 | ||
| Esophagitis, Barrett Esophagus, and Benign Esophageal Masses | 164 | ||
| Benign Conditions Affecting the Trachea | 164 | ||
| Elastofibroma Dorsi | 164 | ||
| Amyloidosis | 165 | ||
| Summary | 165 | ||
| References | 165 | ||
| Abdomen Normal Variations and Benign Conditions\rResulting in Uptake on FDG-PET/CT | 169 | ||
| Key points | 169 | ||
| Introduction | 169 | ||
| Variations in physiologic FDG activity in the abdomen on FDG-PET/CT | 170 | ||
| GI Tract | 170 | ||
| GU Tract | 171 | ||
| Solid Organs | 173 | ||
| Patient preparation to reduce physiologic activity in the GI and GU tracts | 174 | ||
| The effect of medication on variations in FDG activity in the abdomen | 176 | ||
| GI Tract | 176 | ||
| Spleen and Bone Marrow | 177 | ||
| Metabolically active brown adipose tissue, skeletal muscle uptake, and artifacts | 177 | ||
| Benign conditions resulting in uptake on FDG-PET/CT | 178 | ||
| Liver and Biliary Tract | 179 | ||
| Pancreas | 180 | ||
| GI Tract | 180 | ||
| GU Tract | 180 | ||
| Summary | 180 | ||
| References | 181 | ||
| Pelvis Normal Variants and Benign Findings in\rFDG-PET/CT Imaging | 185 | ||
| Key points | 185 | ||
| Introduction | 185 | ||
| Bone Benign Pathology | 186 | ||
| Colon Benign Pathology | 186 | ||
| Bladder Benign Pathology | 188 | ||
| FDG Uptake in Vascular Structures | 188 | ||
| Male pelvis | 188 | ||
| Prostate Benign Pathology | 188 | ||
| Male Reproductive System | 189 | ||
| Female pelvis | 189 | ||
| Normal Variants | 189 | ||
| Uterine Benign Pathology | 190 | ||
| Adnexal Benign Pathology | 191 | ||
| References | 191 | ||
| Normal Variations and Benign Findings in Pediatric 18F-FDG-PET/CT | 195 | ||
| Key points | 195 | ||
| Introduction | 195 | ||
| Patient preparation for pediatric 18F-FDG PET and 18F-FDG PET/CT | 196 | ||
| PET acquisition | 201 | ||
| Special pediatric concerns | 202 | ||
| Image coregistration | 203 | ||
| PET/CT | 203 | ||
| Normal patterns of 18F-FDG uptake in pediatrics | 204 | ||
| Summary | 207 | ||
| References | 207 | ||
| Differential Background Clearance of Fluorodeoxyglucose Activity in Normal Tissues and its Clinical Significance | 209 | ||
| Key points | 209 | ||
| Introduction | 209 | ||
| Subjects and methods | 210 | ||
| Patients | 210 | ||
| Imaging | 210 | ||
| Data Analysis | 210 | ||
| Results | 210 | ||
| Tissues with Decreased FDG Uptake on Delayed Images | 210 | ||
| Tissues with Increased FDG Uptake on Delayed Images | 212 | ||
| Tissues with Nonsignificant Changes in FDG Uptake on Delayed Images | 213 | ||
| RI and Implication for Clinical Practice: An Example | 213 | ||
| Discussion | 214 | ||
| Summary | 215 | ||
| Acknowledgments | 216 | ||
| References | 216 | ||
| Postradiation Changes in Tissues Evaluation by Imaging Studies with\rEmphasis on Fluorodeoxyglucose-PET/\rComputed Tomography and Correlation\rwith Histopathologic Findings | 217 | ||
| Key points | 217 | ||
| Introduction | 217 | ||
| External radiotherapy | 218 | ||
| Central Nervous System | 218 | ||
| Brain | 218 | ||
| Histopathologic features | 218 | ||
| Imaging (non-PET) | 218 | ||
| FDG-PET | 219 | ||
| Spinal cord | 220 | ||
| Fluorodeoxyglucose Positron Emission Tomography/Magnetic Resonance Imaging Current Status, Future Aspects | 237 | ||
| Key points | 237 | ||
| Introduction | 237 | ||
| PET/MR camera basics | 238 | ||
| Index | 253 |